Peptide-drug conjugates (PDCs) are medicines that attach a cancer-fighting payload to a short peptide that seeks out tumor cells. The quick answer: one class is firmly established, as lutetium-177 dotatate, a radioactive peptide conjugate, delayed tumor growth in a 229-patient phase 3 trial and is approved for some neuroendocrine tumors.[3] The first chemotherapy PDC, melflufen, won US approval in 2021 but was withdrawn in 2024 after a survival concern.[5][6] Newer PDCs are in phase 2 trials.[7]
This page is part of our peptide basics hub. Many PDCs are built on ring-shaped peptides; see our guide to cyclic peptides.
Bottom line
- Established: peptide-radionuclide conjugates work in neuroendocrine tumors.[3]
- Cautionary: melflufen improved progression-free survival but not overall survival, and lost its approval.[5][6]
- Promising: bicyclic peptide conjugates show responses in early bladder cancer trials.[7]
- Unproven: brain-penetrating PDCs missed a key response goal in phase 2.[8]
How peptide-drug conjugates work
- Homing peptide: binds a receptor that is overexpressed on cancer cells, such as somatostatin receptors or nectin-4.
- Linker: holds the payload until it reaches the tumor, then releases it, for example when cut by tumor enzymes or exposed to acidity inside cells.
- Payload: a chemotherapy drug, a cell toxin, or a radioactive atom.
Compared with antibody-drug conjugates, PDCs are much smaller. That helps them penetrate solid tumors and makes them cheaper to manufacture, but they are cleared from the blood faster and kidneys can take up some of the dose.[1] Linker choice is a major design problem: release too early and healthy tissue is exposed; too late and the drug never works.[2]
PDCs vs antibody-drug conjugates
Antibody-drug conjugates (ADCs) are the better-known cousin. An antibody is many times larger than a typical targeting peptide. That size keeps ADCs in the bloodstream for days to weeks, which gives them time to find tumor cells, but it also slows their movement into dense tumors and makes them expensive to produce in living cells.[1]
PDCs are made by chemical synthesis, so their structure can be tuned precisely and batches are more uniform. Their small size means quick tumor entry, but also quick removal by the kidneys. Developers try to balance this with ring-shaped peptides, which resist breakdown, and with linkers matched to conditions inside the tumor.[1][2] Whether these advantages translate into longer survival is still being tested; so far, the strongest evidence comes from the radioactive class.
Key PDCs at a glance
| PDC | Peptide target | Payload | Status |
|---|---|---|---|
| Lutetium-177 dotatate | Somatostatin receptors | Radioactive lutetium-177 | FDA-approved for some neuroendocrine tumors[3] |
| Melflufen | Enters cells, then cut by peptidases | Melphalan (chemotherapy) | Approved 2021; approval withdrawn 2024[6] |
| Zelenectide pevedotin | Nectin-4 | MMAE (cell toxin) | Phase 2[7][9] |
| ANG1005 | LRP1 (to cross the blood-brain barrier) | Paclitaxel | Phase 2 completed[8] |
Key studies
Lutetium-177 dotatate (NETTER-1). This conjugate links a somatostatin-like peptide to radioactive lutetium, which irradiates tumor cells that carry somatostatin receptors. In 229 patients with advanced midgut neuroendocrine tumors, the estimated 20-month progression-free rate was 65.2% with the conjugate vs 10.8% with high-dose octreotide alone, and response rates were 18% vs 3%. Severe low blood counts were uncommon.[3] Our peptide radiotracers guide explains how the same peptide is used for scans.
Melflufen (OCEAN). Melflufen is a peptide conjugate that targets enzymes called aminopeptidases. Once inside tumor cells, it is cut by peptidases, releasing the chemotherapy melphalan, which becomes trapped there.[4] In OCEAN, 495 people with relapsed myeloma were randomized to melflufen or pomalidomide, each with dexamethasone. Median progression-free survival was 6.8 vs 4.9 months, favoring melflufen. But median overall survival was 19.8 months with melflufen vs 25.0 months with pomalidomide. Low platelets occurred in 63% vs 11%.[5] FDA, which had granted accelerated approval, proposed withdrawal and published its final decision withdrawing approval in April 2024.[6]
Zelenectide pevedotin (Duravelo-1). This “Bicycle” conjugate uses a small peptide constrained into two rings to target nectin-4, a protein abundant on bladder cancer cells, and carries the toxin MMAE. In 49 patients in the dose-escalation phase, the response rate was 24% across tumor types and 38% in urothelial (bladder tract) cancer, with a median response duration of 11.1 months. Nausea (49%), fatigue (39%) and nerve damage (33%) were common, mostly mild.[7]
ANG1005. This conjugate links paclitaxel to a peptide designed to ride a transport receptor across the blood-brain barrier. In a phase 2 study of breast cancer that had spread to the brain, investigators reported disease control in most evaluable patients, but the independent-review brain response rate was 8%, and the trial did not meet its preset response target.[8]
Side effects
The payload is still a potent drug. Common problems include low blood counts (especially platelets with melflufen), nausea and fatigue, nerve damage with MMAE payloads, and kidney exposure with radioactive conjugates.[3][5][7] Targeting reduces, but doesn’t remove, effects on healthy tissue.
Limitations
- Most PDC data come from single-arm or open-label trials.
- Progression-free survival gains don’t always mean people live longer, as melflufen showed.[5]
- Fast clearance can limit how much payload reaches the tumor.[1]
What’s next
Duravelo-2, a phase 2 trial of zelenectide pevedotin in advanced urothelial cancer, enrolled 375 participants and is active but no longer recruiting.[9] Separate phase 2 studies are testing it in breast and lung cancers with nectin-4 changes. Researchers are also using cell-penetrating peptides to carry drugs inside cells and pairing peptides with peptide vaccines and immunotherapy. For how peptides are modified to survive in the body, see natural vs synthetic peptides.
Questions to discuss with a clinician
- Does my tumor express a target, such as somatostatin receptors or nectin-4, that a PDC could use?
- How does a PDC compare with standard chemotherapy or an antibody-drug conjugate for me?
- What monitoring is needed for blood counts, nerves or kidneys?
- Am I eligible for a PDC clinical trial?
